88 Chapter 4 ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ m3339 (2020) doi:10.1136/bmj.m3339. 23. Wu, C. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine 180, 934 (2020). 24. Dadashi, M. et al. COVID-19 and Influenza Co-infection: A Systematic Review and MetaAnalysis. Frontiers in Medicine 8, 681469 (2021). 25. Dao, T. L., Hoang, V. T., Colson, P., Million, M. & Gautret, P. Co-infection of SARS-CoV-2 and influenza viruses: A systematic review and meta-analysis. Journal of Clinical Virology Plus 1, 100036 (2021). 26. Mo, P. et al. Clinical Characteristics of Refractory Coronavirus Disease 2019 in Wuhan, China. Clinical Infectious Diseases 73, e4208–e4213 (2021). 27. Ding, Q., Lu, P., Fan, Y., Xia, Y. & Liu, M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. Journal of Medical Virology 92, 1549–1555 (2020). 28. Chekuri, S. et al. SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study. Journal of Antimicrobial Chemotherapy 76, iii12–iii19 (2021). 29. Drake, T. M. et al. Influenza infection in patients hospitalised with COVID-19: Rapid report from CO-CIN data. (2020). 30. Aitken, C. & Jeffries, D. J. Nosocomial spread of viral disease. Clinical Microbiology Reviews 14, 528–546 (2001). 31. Thwaites, R. S. et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology 6, eabg9873 (2021).
RkJQdWJsaXNoZXIy MTk4NDMw